Healthcare -
Biotechnology - NASDAQ - US
$ 14.58
-7.6 %
$ 2.48 B
Market Cap
-5.56
P/E
1. INTRINSIC VALUE
Balance Sheet
Immunovant, Inc.
| Current Assets | 666 M |
| Cash & Short-Term Investments | 635 M |
| Receivables | 5.5 M |
| Other Current Assets | 24.9 M |
| Non-Current Assets | 595 K |
| Long-Term Investments | 0 |
| PP&E | 595 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 48.6 M |
| Accounts Payable | 7.16 M |
| Short-Term Debt | 276 K |
| Other Current Liabilities | 41.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Immunovant, Inc.
| Revenue | 0 |
| Cost Of Revenue | 231 K |
| Gross Profit | -231 K |
| Operating Expenses | 283 M |
| Operating Income | -283 M |
| Other Expenses | -23.4 M |
| Net Income | -259 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immunovant, Inc.
| Net Income | -259 M |
| Depreciation & Amortization | 231 K |
| Capital Expenditures | -360 K |
| Stock-Based Compensation | 41.1 M |
| Change in Working Capital | 2.63 M |
| Others | 2.54 M |
| Free Cash Flow | -215 M |
Wall Street Analysts Price Targets
Immunovant, Inc.
Wall Street analysts predict an average 1-year price target for IMVT of $50.5 , with forecasts ranging from
a
low of
$46 to a high of $57 .
IMVT Lowest Price Target
Wall Street Target
46 USD
215.50%
IMVT Average Price Target
Wall Street Target
50.5 USD
246.36%
IMVT Highest Price Target
Wall Street Target
57 USD
290.95%
4. DIVIDEND
ANALYSIS
IMVT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Immunovant, Inc.
Sold
0-3 MONTHS
1.24 M USD 6
3-6 MONTHS
2.2 M USD 8
6-9 MONTHS
2.09 M USD 7
9-12 MONTHS
3.77 M USD 7
Bought
337 M USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
zacks.com
- 2 weeks ago
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
seekingalpha.com
- 2 weeks ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
prnewswire.com
- 2 weeks ago
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
investors.com
- 2 weeks ago
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
reuters.com
- 2 weeks ago
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
globenewswire.com
- 2 weeks ago
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
globenewswire.com
- 2 weeks ago
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 1 month ago
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
zacks.com
- 1 month ago
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
globenewswire.com
- 1 month ago
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
prnewswire.com
- 2 months ago
A Huge Biotech Purchase Highlights New Year's Insider Buying
The year started off slow as far as insider purchases go.
247wallst.com
- 2 months ago
8. Profile
Summary
Immunovant, Inc. IMVT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.48 B
Dividend Yield
0.00%
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Contact
320 West 37th Street, New York, NY, 10018
https://immunovant.com
IPO
Date
June 21, 2019
Employees
207
Officers
Ms. Melanie Gloria B.S.N.
Chief Operating Officer
Mr. Andy Deig
Senior Vice President of Strategic Finance
Dr. Michael Geffner M.B.A., M.D., Ph.D.
Chief Medical Officer
Ms. Christine Blodgett
Senior Vice President of Human Resources
Dr. Peter Salzmann M.B.A., M.D.
Chief Executive Officer & Director
Dr. Jay S. Stout Ph.D.
Chief Technology Officer
Ms. Lauren Schrier M.B.A.
Vice President of Marketing
Dr. Frank M. Torti M.B.A., M.D.
Executive Chairperson of the Board
Ms. Eva Renee Barnett M.B.A.
Chief Financial Officer
Mr. Christopher A. Van Tuyl Esq., J.D.
Chief Legal Officer & Corporate Secretary